No Data
Hong Kong technology stocks are being targeted by Short Sell, with Meituan's short sold shares nearly doubling in three days.
1. Which Hong Kong Technology stocks have been significantly shorted by bears recently? 2. How do Institutions view the subsequent performance?
In "The Big Broker", CICC lists the adjustment and weight changes of the Hang Seng Tech Index constituent stocks along with the forecast of changes in passive capital (table).
CICC released a report stating that the Hang Seng Index Company announced the quarterly index adjustment results for the Hang Seng Tech Index last Friday (16th), effective from June 9 (Monday). This adjustment includes BYD (01211.HK) with a weight of 8%; CHINA LIT (00772.HK) was removed, previously having a weight of 0.49%. The number of constituent stocks remains unchanged at 30. Stocks │ Hang Seng Tech Index weight change forecast │ Potential passive capital change BYD (01211.HK) ※│0%->8%│ Inflow of 1.998 billion USD NTES-S (09999.HK) │ 4.62%->
Hong Kong stocks fluctuated | JD HEALTH (06618) rose over 4% as the first quarter performance significantly exceeded expectations. Institutions recommend paying attention to the expansion of instant retail layout.
JD HEALTH (06618) rose over 4%, as of the time of writing, up 4.49%, reported at 40.7 Hong Kong dollars, with a transaction value of 0.343 billion Hong Kong dollars.
JD HEALTH (6618.HK): Revenue and profit have shown strong year-on-year growth, and AI + Medical applications continue to be implemented.
Event: JD HEALTH released the first quarter announcement for 2025 on May 13, 2025: In Q1 2025, the company achieved revenue of 16.6 billion yuan, a year-on-year increase of 25.5%; operating profit was 1.1 billion yuan, a year-on-year increase.
Nomura Adjusts JD Health International's Price Target to HK$44 From HK$41.50, Keeps at Buy
[Brokerage Focus] HAITONG INT'L maintains a "Buy" rating on JD HEALTH (06618), citing an improvement in the company's bargaining power and a continuous release of profit margins under scale effects.
Jinwu Financial News | HAITONG INT'L released a Research Report indicating that JD HEALTH (06618) achieved a record-breaking revenue scale of 16.65 billion yuan in Q1 2025 (YoY +25.5%, QoQ +0.8%), outperforming the annual guidance (double-digit growth, according to the public Earnings Conference of 2024). According to management, the acceleration in revenue is attributed to: 1) influenza; 2) growth in original research drugs for the "three highs"; 3) growth in health products and increased advertising investment from brand owners. The firm stated that bargaining power has improved, and profit margins continue to be released under economies of scale. In Q1 2025, the company achieved an operating profit of 1.07 billion yuan (+1.
